No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 40 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 8.1x · 10Y median 24.6x · 3rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:03:50.798Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:03:50.798Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:03:50.798Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:03:50.798Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:03:50.798Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ProQR Therapeutics N.V. (PRQR) stock was $1.65 as of Oct 6, 2026, 1:00 PM EDT, down 1.50% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -31.7% · 3-year avg +8.7%/yr · 5-year avg -26.2%/yr
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders.
Biotechnology · Leiden, ZH
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · EUR
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.11
Revenue Est.
$4.30M
Last Quarter Results
EPS
$-0.09
vs Estimate
$-0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRQR | $173.23M | $1.65 | -1.50% | -31.71% | -26.23% | -13.48% | N/A |
| 2DTIL | $172.83M | $6.26 | -0.77% | +15.91% | -54.84% | N/A | vs PRQR |
| 3CUE | $172.49M | $23.75 | -2.52% | +11.33% | -42.42% | N/A | vs PRQR |
| 4CMPX | $175.21M | $0.97 | +1.28% | -73.87% | -22.79% | N/A | vs PRQR |
| 5ORGO | $171.14M | $1.33 | +3.10% | -69.76% | -37.41% | N/A | vs PRQR |
| 6DERM | $176.67M | $6.42 | -4.05% | -8.69% | N/A | N/A | vs PRQR |
forward FY estimate
N/A
$10.00M
vs Estimate
$4.56M
Consensus Rating
Based on 9 analysts
Average Price Target
$7.78
+372.8% upside
Low
$3.00
Current
$1.65
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR -0.12 | EUR -0.10 | EUR -0.09 | 3 |
| Quarter ending Dec 2026 | EUR -0.15 | EUR -0.11 | EUR -0.08 | 2 |
| Quarter ending Mar 2027 | EUR -0.14 | EUR -0.12 | EUR -0.08 | 1 |
| Quarter ending Jun 2027 | EUR -0.15 | EUR -0.13 | EUR -0.09 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | EUR -0.50 | EUR -0.42 | EUR -0.35 | 5 |
| FY 2027 | EUR -0.75 | EUR -0.49 | EUR -0.39 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR 3.61M | EUR 3.81M | EUR 4.11M | 4 |
| Quarter ending Dec 2026 | EUR 3.34M | EUR 3.59M | EUR 3.76M | 4 |
| Quarter ending Mar 2027 | EUR 2.80M | EUR 3.70M | EUR 4.14M | 2 |
| Quarter ending Jun 2027 | EUR 2.80M | EUR 3.70M | EUR 4.14M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | EUR 16.34M | EUR 16.67M | EUR 17.08M | 5 |
| FY 2027 | EUR 15.52M | EUR 19.50M | EUR 21.16M | 5 |
